Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Oct 9, 2007

Exelixis, Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

Calif., Oct. 8 , 2007 - Exelixis, Inc. (Nasdaq: EXEL ) announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Fran cisco... Exelixis' Press Release -